6,888 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Capula Management Ltd

Key Points

• Capula Management Ltd acquired a new position of 6,888 shares in Alnylam during the third quarter, valued at approximately $3.14 million.
• Alnylam reported quarterly EPS of $1.25, missing estimates ($1.43) and posting $1.10 billion in revenue (vs. $1.16B expected) despite revenue rising 84.9% year‑over‑year; analysts maintain a "Moderate Buy" consensus with an average price target of $477.96.
• Insider selling totaled 53,923 shares worth $18.07 million in the last quarter, while institutional investors own about 92.97% of the stock (insiders own 1.5%).

Capula Management Ltd acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 6,888 shares of the biopharmaceutical company's stock, valued at approximately $3,141,000.

Several other large investors also recently added to or reduced their stakes in ALNY. Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $27,000. Ameriflex Group Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $32,000. ORG Partners LLC raised its position in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 33 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at $36,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Down 1.2%

ALNY opened at $313.41 on Friday. The firm has a market cap of $41.56 billion, a P/E ratio of 183.28 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The business has a 50 day moving average price of $344.35 and a 200 day moving average price of $409.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the business earned ($0.65) EPS. The company's revenue for the quarter was up 84.9% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ALNY shares. Freedom Capital upgraded Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 17th. Leerink Partners reduced their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a "market perform" rating for the company in a research report on Monday, December 15th. Needham & Company LLC lowered their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating on the stock in a research note on Thursday, February 12th. Royal Bank Of Canada dropped their target price on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 20th. Finally, Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an "outperform" rating and a $500.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $477.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. This trade represents a 7.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Tolga Tanguler sold 1,598 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the transaction, the executive vice president directly owned 36,606 shares of the company's stock, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,923 shares of company stock worth $18,072,087 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.